Standard BioTools (LAB) Stock Price, News & Analysis

Company Overview

Standard BioTools Inc. (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.

The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis. Its portfolio also includes Hyperion imaging technologies and microfluidics-based tools designed to help researchers study cells, tissues and molecular characteristics.

Standard BioTools serves academic, government, clinical research and biopharmaceutical customers internationally. The company was formerly known as Fluidigm and adopted the Standard BioTools name in 2022. In 2024, it completed a combination with SomaLogic, expanding its capabilities in large-scale proteomic analysis. Michael Egholm serves as the company’s chief executive officer.

Key Stats

• Today's Range: $0.64 to $0.72
• 50-Day Range: $0.60 to $0.77
• 52-Week Range: $0.59 to $1.72
• Volume: 406,133 shs
• Average Volume: 835,763 shs
• Market Capitalization: $253.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Standard BioTools Stock Analysis - MarketRank™

Standard BioTools scored higher than 58% of companies evaluated by MarketBeat, and ranked 627th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Standard BioTools has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Standard BioTools has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Standard BioTools is 2.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Standard BioTools is 2.92, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.37.

Price to Book Value per Share Ratio

Standard BioTools has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of Standard BioTools has been sold short.

Short Interest Ratio / Days to Cover

Standard BioTools has a short interest ratio ("days to cover") of 3.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Standard BioTools has recently decreased by 11.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Standard BioTools does not currently pay a dividend.

Dividend Growth

Standard BioTools does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.29

News Sentiment

Standard BioTools has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Standard BioTools this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $47,250.00 in company stock, which represents 0.0186% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,250.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

26.81% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/03/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:LAB
• Previous Symbol: NASDAQ:SLGC
• CIK: 1162194
• Web: www.standardbio.com
• Phone: (650) 266-6000
• Fax: 650-871-7152
• Employees: 389
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): $0.22
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.90 million
• Net Margins: 157.62%
• Pretax Margin: -86.50%
• Return on Equity: -5.61%
• Return on Assets: -4.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.75
• Quick Ratio: 9.40

Sales & Book Value

• Annual Sales: $85.33 million
• Price / Sales: 2.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 394,790,000
• Free Float: 288,947,000
• Market Cap: $253.85 million
• Optionable: Optionable
• Beta: 1.52